-

Schrödinger to Host Conference Call to Discuss Third Quarter 2021 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide an update on its business.

The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To participate in the live call, please dial (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 2484045. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

Contacts

Jaren Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Industry:

Schrödinger

NASDAQ:SDGR
Release Summary
Schrödinger today announced that it will report third quarter 2021 financial results on November 10, 2021.
Release Versions
English

Contacts

Jaren Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

More News From Schrödinger

Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration’s (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA’s roadmap encourages a number of computational approaches to predict drug properties. Schrödinger’s widely used computational platform enables highly accur...

Schrödinger to Present Preclinical Data at AACR Annual Meeting

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that new preclinical data on SGR-3515 and SGR-4174 will be presented at the AACR Annual Meeting 2025....

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of...
Back to Newsroom